The use of SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, and ipragliflozin) significantly reduces hyperglycemia, body weight, glycated hemoglobin (HbA1C), blood pressure (BP), hyperinsulinemia, inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), monocyte chemotactic protein-1 (MCP-1), and C-reactive protein (CRP)), hyperfiltration, natriuresis, oxidative stress (OS), and glycosuria [202, 203, 207–210]. The gene discussed is TNF; the disease is Hyperinsulinemia.